French biotechnology company specializing in the treatment of brain disordersAelis Farma reported Wednesdaythe results from its clinical Phase 2B trial with AEF0117, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe cannabis use disorder (CUD). The study did not meet its main goal, which was to reduce participants’ cannabis use to one day or less per week. It also failed to meet other goals, such as getting participants to stop using marijuana completely or reduce their consumption to two days or less per week. “It is noteworthy that there was a very …
